ArticleFrontiers in artificial intelligence2025
An artificial intelligence model for early-stage breast cancer classification from histopathological biopsy images.
Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate identification of breast cancer subtypes is essential for guiding treatment decisions and improving patient outcomes. In current clinical practice, determining histological subtypes often requires additional invasive procedures, delaying treatment initiation. This study proposes a deep learning-based model built on a DenseNet121 backbone with a multi-scale feature fusion strategy, designed to classify breast cancer from histopathological biopsy images. Trained and evaluated on the publicly available BreaKHis dataset using 5-fold cross-validation, the model achieved a binary classification accuracy of 97.1%, and subtype classification accuracies of 93.8% for benign tumors and 92.0% for malignant tumors. These results demonstrate the model's ability to capture morphological cues at multiple levels of abstraction and highlight its potential as a diagnostic support tool in digital pathology workflows.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.